Saturday 17 October 2026
Export MIST’s income statement to Excel — free account
Milestone Pharmaceuticals Inc.
MIST Healthcare Biotechnology
Milestone Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, up 54.6% from fiscal 2023. In the quarter to June 2026, revenue fell 62.7%, EPS fell 5.00%, free cash flow fell 80.8% and total debt rose 7.19%, each against the same quarter a year earlier.
0.71
0.09
−11.25%
Follow MIST
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(260.65%) | (229.65%) | (456.88%) | (35,522.62%) | |
| (68.07%) | (66.71%) | (53.49%) | (73.36%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(76.05%) | (64.05%) | (39.79%) | (52.97%) | |
Average Days of Receivables |
0.00 | 0.00 | 177.29 | 237.45 | |
Free Cash Flow per Share |
(0.45) | (0.59) | (0.40) | (0.44) | |
Free Cash Flow |
(43.15) | (49.34) | (51.48) | (61.65) | |
Capital Expenditures |
(0.04) | (0.30) | (0.34) | (0.36) | |
| Other line items | |||||
Cash ROIC |
(27.09%) | (24.08%) | (18.49%) | (24.85%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 2.97 | 2.42 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.01 | 0.01 | |
Inventory Turnover |
— | — | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 45,729.94 | 32,826.70 | |
Days of Inventory on Hand |
— | 0.00 | 8,331.13 | 18,335.43 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 262.60% | 306.23% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 271.42% | 579.89% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 118.50% | 140.12% | |
Interest Coverage |
(15.17) | (16.19) | (9.28) | (7.25) | |
Operating CF/Net income |
0.74 | 0.78 | 0.75 | 0.73 | |
Depreciation/Fixed assets |
0.78 | 0.22 | 0.29 | 0.37 | |
Capex/Depreciation |
(0.39) | (2.65) | (2.38) | (2.07) | |
Revenue per Share |
0.00 | 0.00 | 0.05 | 0.04 | |
Operating CF per Share |
(0.45) | (0.58) | (0.39) | (0.44) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.05 | 0.07 |
Columns are period end dates